Scholars Central

EditorialPublished 27 Aug 2020

Putative/New Antipsychotics

Authors: Peter F. Buckley

Clinical Schizophrenia & Related Psychoses

Volume 11 · Issue 2 · Pages 27–28

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

The U.S. Food and Drug Administration (FDA) has approved lurasidone for use in adolescents (aged 13–17 years) with schizophrenia. The FDA’s extension of lurasidone to the adolescent population was based on the positive efficacy results from a six-week, placebo-controlled trial of 40 or 80 mg/day. Both doses of lurasidone were effective.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Similar by topic

More from this journal

The newest in Clinical Schizophrenia & Related Psychoses.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalClinical Schizophrenia & Related Psychoses
  • SubjectMental Health and Psychology
  • BylineArticles whose byline prints “Peter F. Buckley”

For authors and organisers

Publish, present and keep up with your field

Find the right journal for your paper and submit your manuscript.

Photo: Pexels